Official Title
An Extended Access Program (EAP) for Rufinamide in Pediatric Participants With Inadequately Controlled Lennox-Gastaut Syndrome
Brief Summary

This is an extended access study for participants who have completed Rufinamide Study E2080-G000-303 to continue to have access to rufinamide until it becomes commercially available in Poland or until no participants remain in the EAP.

Available
Individual Patients
Treatment IND/Protocol
Lennox Gastaut Syndrome

Drug: Rufinamide
Rufinamide up to 45 milligram per kilogram per day (mg/kg/day).

Eligibility Criteria

Inclusion Criteria:

- Participants who were on rufinamide treatment and have completed Study E2080-G000-303 in Poland.

Exclusion Criteria:

- Participants were randomized to the other antiepileptic drug (AED) treatment group in study E2080-G000-303.

Eligibility Gender
All
Eligibility Age
Minimum: 4 Years
Countries
Poland
Contacts

Eisai Medical Information
1-888-274-2378
esi_medinfo@eisai.com

NCT Number
Keywords
Central Nervous System
E2080
Rufinamide
Epilepsy
Seizures
Brain Diseases
MeSH Terms
Lennox Gastaut Syndrome
Syndrome
Rufinamide